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TREATMENT WITH MEBENDAZOLE IS NOT ASSOCIATED WITH DISTAL MIGRATION OF ADULT
Angiostrongylus costaricensis IN THE MURINE EXPERIMENTAL INFECTION
Márcia Bohrer MENTZ(1), Carlos GRAEFF-TEIXEIRA(2) & Cinara Tentardini GARRIDO(2)
SUMMARY
Abdominal angiostrongyliasis is a zoonotic infection produced by a metastrongylid intra-arterial nematode, Angiostrongylus
costaricensis. Human accidental infection may result in abdominal lesions and treatment with anti-helminthics is contra-indicated
because of potential higher morbidity with excitement or death of worms inside vessels. To evaluate the effect of mebendazole on
localization of the worms, male Swiss mice, 5 week-old, were infected with 10 third stage larvae per animal. Twelve infected mice
were treated with oral mebendazol, at 5 mg/kg/day, for 5 consecutive days, begining 22 days after inoculation. As control groups, 12
infected but non-treated mice and other 12 non-infected and non-treated mice were studied. The findings at necropsy were, respectively
for the treated (T) and control (C) groups: 92% and 80% of the worms were inside the cecal mesenteric arterial branch; 8% and 10%
were located inside the aorta. Only in the group C some worms (10%) were found inside the portal vein or splenic artery. These data
indicate that treatment with mebendazole does not lead to distal or ectopic migration of A. costaricensis worms.
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INTRODUCTION
Angiostrongylus costaricensis (Nematoda: Angiostrongylidae),
MORERA & CESPEDES 1971, is a nematode that lives inside the ileo-
colic branches of mesenteric artery of wild rodents, like the cotton rat,
Sigmodon hispidus. The parasite, its cycle and the disease were first
described in Costa Rica (CESPEDES et al., 1967; MORERA, 1973).
Man is an accidental host, that may become infected by ingestion of
food or water contaminated with third stage larvae, which may be present
in the mucous secretion of veronicellid slugs, the most important
intermediate host (MORERA, 1985).
The geographic range of the parasitosis includes most of the countries
in the Americas, from the south of the United States to the north of
Argentina (DEMO & PESSAT, 1986; MORERA, 1988). In Brazil, the
occurrence of abdominal angiostrongyliasis has been reported since 1975
(ZILIOTTO et al., 1975). The worm causes in man an infection called
abdominal angiostrongyliasis, a parasitic disease characterized by a
granulomatous inflammatory reaction with heavy eosinophilic infiltration
of intestinal wall, especially in the ileo-cecal region (MORERA, 1967;
GRAEFF-TEIXEIRA et al., 1991). Until now there is no effective
medical treatment and there is even a relative contra-indication for the
use of anti-helminthics, based on data reported by MORERA &
BONTEMPO (1985) suggesting that parasites were excited by the drugs
instead of killed, causing erratic migration and worsening of the lesions.
After these, some drug trials have demonstrated a predominant larvicidal
effect, but none of those experiments was concerned with the possibility
of migration of the adult worm after treatment, as it is the case in the
present study, with mebendazole.
MATERIALS AND METHODS
The infective third-stage Angiostrongylus costaricensis larvae (L3),
Santa Rosa strain, were inoculated through a metal canula, into 6 week-
old male Swiss mice (Mus domesticus domesticus). The larvae were
obtained from experimentally infected Phyllocaulis soleiformis slugs.
The molluscs were digested in a 0.03% pepsin (Sigma P-7125) solution
in 0.7% HCl for 2 hours at 37 oC. Two groups (T and C) of 12 mice each,
were inoculated with 10 L3 per animal. The first group (T), was treated
with five successive doses of mebendazole (methyl 5-benzoyl-2-
benzimidazole-carbamate) at 5 mg/kg/day, starting 22 days post-infection
(dpi). Mebendazole (BYC, Dinamarc) was suspended in 100 µL of
distilled water and given orally with a metal catheter. To both control
groups, C (infected and non-treated) and N (non-infected and non-treated)
only 100 µL of distilled water was administered per os.
The animals were kept on standard laboratory conditions with food
and tap water ad libitum. In order to confirm the infection, after 21 dpi
we started daily individual observation of the number of first larvae stage
(L1) in feces, for seven days, using the Baermann-Moraes modified
method. All surviving mice were sacrificed by CO2 inhalation at 27 dpi
and examined for the presence, number and location of adult worms.
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RESULTS AND DISCUSSION
The results are shown in the Table 1. Both in treated and non-treated
groups most of the worms were found in their usual location, the main
branches of mesenteric artery.
Efficacy of a chemotherapeutic treatment is influenced by various
factors including route, dosage and regimen of the treatment. In addition,
in the treatment of the diseases by tissue dwelling parasites, allergenic
components of killed worms may cause adverse effects on the host
(HAWKING, 1979; JOUBERT et al., 1985; HAYASHI, 1987). Therefore,
effective treatment should only be established after these factors are taken
into account through basic studies using experimental models.
In several experimental studies with Angiostrongylus spp, a number
of parameters have been observed, like body weight, host death, relative
spleen weight, pathologic changes on the serosal surface of cecum and
ileum, hematologic examination, larvae elimination in feces and eggs in
intestinal wall, as well as the number of recovered worms, their body
length and morphologic changes (TERADA et al., 1993). Study on the
localization of worms as an effect of the drug has never been performed
with abdominal angiostrongyliasis.
Recent studies about mode of action of mebendazole (methyl 5-
benzoyl-2-benzimidazole-carbamate) suggested interruption of
microtubular function as its primary mechanism of action. It secondarily
inhibits glucose uptake, fumarate redutase activity, egg hatching and
larval development (REW & FETTERER, 1986). Killing effect is thought
to result not only from drug action but also from the host’s immune
response as suggested initially by TERADA et al. (1992).
TUNGTRONGCHITR et al. (1993a) suggested that different
mechanisms resulting in damage to the worms and to the host would be
related to different regimens of mebendazole. When host mice were
treated successively with higher doses, worms would be killed abruptly
due to anthelmintic action of mebendazole, causing rather severe side
effects. When mice were treated intermittently with lower doses, the
worms were weakened by the anthelmintic and died more gradually
through a combination of drug action and host defense, resulting in fewer
side effects. A daily dose of 5 mg/Kg was selected because its efficacy
and safety to treat murine angiostrongyliasis in the adult stage was
demonstrated by other authors (TERADA et al., 1993;
TUNGTRONGCHITR et al., 1993a).
Treatment did not reduce the number of recovered worms: 36 in the
mebendazole group and 30 in control group. This seems to confirm the
idea that mebendazole is predominantly a larvicidal drug, with little
killing effect at adult stages, as shown by TERADA et al. (1992): the
worm recovery decreased only with earlier administration, such as 10-
25 days p.i.
TUNGTRONGCHITR et al. (1993b) showed that the treatment with
mebendazole, even with some reduction in the number of worms, could
not completely prevent host death, probably because of allergenic
reactions to substances released by dead worms. In the present work,
mortality was 83% in the non-treated infected control group (C group)
and 67% in mebendazole treated group (T group). This difference in
mortality can not be attributed to a killing effect on adult worms, since
their number was not reduced, but may be linked to the reduction both
in the number of animals with L1 elimination (C group: 62.5%; T group:
100%). It could be an effect of mebendazole on egg formation and/or
oviposition, as previously suggested by TERADA et al. (1993). These
authors demonstrated that mebendazole can completely abolish larval
output, a result only partially now reproduced, with the same successive
daily dosis.
In both groups, most of the worms were located in the main branches
of mesenteric artery: 24 (80%) and 33 (92%), respectively in control
and treated groups (Table 1), in accordance with the data from TERADA
et al. (1993). Only 8% of the worms in treated animals were found in
the thoracic aorta, that should not be considered an ectopic location since
one main route (lymphatic-arterial) for development of A. costaricensis
includes the aorta (MOTA & LENZI, 1995). Even if one considers it as
ectopic location, it is not attributable to mebendazole, since 10% of worms
in the control group were also in that location.
In conclusion, the data now reported does not support the hypothesis
that mebendazole induces ectopic migration of the A. costaricensis adult
worms in the murine model.
Table 1
Evaluation of mebendazole (five oral successive doses of 5 mg/kg/day) on morbidity, mortality, larvae elimination and localization of adult worms in the murine
experimental infection with Angiostrongylus costaricensis
Groups/ Parameters Non-treated Treated Mebendazole Non-infected
Infected mice  10/10  08/08
Surviving mice  10/12  08/10  12/12
Mortality  83%  67%  0%
Number of worms recovered  30 36  0
Localization of worms:
Mesenteric artery 24 (80%) 33 (92%)
Thoracic aorta 03 (10%) 03 (08%)
Splenic and portal artery 03 (10%) 00 (0%)
Animals with L1 in feces  10/10 (100%)  05/08 (62.5%)  0%
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RESUMO
O tratamento com mebendazol não está associado a migração
distal de adultos de Angiostrongylus costaricensis na infecção
experimental murina
Angiostrongilíase abdominal é uma zoonose causada por um
metastrongilídeo intra-arterial, o Angiostrongylus costaricensis. Infecção
acidental humana pode resultar em doença abdominal e o tratamento
com anti-helmínticos é contra-indicado pela possibilidade de
agravamento das lesões com a excitação ou morte dos vermes intra-
vasculares. Para avaliar o efeito do mebendazole sobre a localização dos
vermes, camundongos Swiss machos, com 5 semanas de idade foram
infectados individualmente com 10 larvas de terceiro estágio. Doze deles
foram tratados 22 dias após a infecção, com mebendazole, na dose de 5
mg/kg/dia, por 5 dias consecutivos. Igual número de camundongos
infectados, não tratados e um terceiro grupo de animais não infectados e
não tratados, serviram como grupos controles. À necrópsia observaram-
se os seguintes resultados: a proporção de vermes adultos encontrados
na artéria mesentérica do ceco e cólon foi de 80% no grupo C e 92% no
grupo T. A proporção de vermes adultos encontrados na aorta torácica
foi de 10% no grupo C e de 8% no grupo T. No grupo C, 10% dos
vermes também foram encontrados na veia porta e na artéria esplênica.
Estes resultados indicam que o mebendazole não induz migração ectópica
ou distal do Angiostrongylus costaricensis.
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